INFLARX NV (NASDAQ:IFRX) reported second-quarter 2026 results that missed analyst expectations on both the top and bottom lines, and the stock is being punished in pre-market trading. The company posted a non-GAAP loss per share of $0.095 against consensus estimates for a loss of $0.060, while revenue came in at zero versus a $3.57 million expectation, a gap largely tied to the wind-down of U.S. commercialization efforts.
Revenue and EPS versus estimates
The quarterly numbers represent a meaningful shortfall relative to the sell-side model. In the three months ended June 30, 2026, the company generated no product revenue, and costs remained elevated as clinical work on izicopan and vilobelimab continued.
- Reported non-GAAP EPS: -$0.095 vs. -$0.060 consensus
- Reported revenue: $0.0 vs. $3.57 million consensus
- Pre-market movement: -5.1%
- One-month share performance: -18.1%
- One-week share performance: +7.3%
The revenue miss was expected to some degree because the company exited commercial sales activities for vilobelimab at the end of 2025. Still, the size of the EPS gap and the absence of recognized revenue in a quarter where analysts had modeled for some contribution left the report comfortably below expectations.
What the press release highlighted
Clinically, management used the update to emphasize momentum around izicopan, the oral C5a receptor inhibitor that is now being positioned as the core growth driver. Phase 2 planning in ANCA-associated vasculitis (AAV) is underway, and the company is also evaluating izicopan in several renal indications, including atypical hemolytic uremic syndrome, IgA nephropathy and C3 glomerulopathy. Initial proof-of-concept data from those open-label studies are targeted for 2027.
- Research and development expenses for the first half fell to EUR 8.9 million from EUR 14.2 million a year earlier.
- Cash, cash equivalents and marketable securities were EUR 158.4 million at June 30, enough to fund operations through 2029.
- A May registered direct offering raised net proceeds of approximately EUR 119.3 million.
- The company plans a virtual Capital Markets Day on October 8, 2026.
The press release also drew attention to new preclinical data indicating that izicopan produces lower reactive metabolite formation than the marketed C5aR inhibitor avacopan, a potential safety differentiator. Following the EMA's CHMP recommendation to revoke marketing authorization for Tavneos in the EU, InflaRx has signaled it will engage with regulators on the most efficient development path for AAV in Europe, using both izicopan and vilobelimab.
Market reaction and outlook
The pre-market decline suggests investors were focused on the magnitude of the financial miss rather than the pipeline narrative. The company did not provide formal financial guidance in the release, so there is no updated company outlook to compare against the sell-side estimates for the upcoming quarters. That absence, combined with the wide earnings gap, likely leaves the initial trading reaction driven by the reported results themselves.
For investors who want to dig into the historical earnings behavior of the stock, a full earnings history is available. Those looking for the latest consensus expectations and forward projections can also review the current estimates page.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss Estimates
INFLARX NV (NASDAQ:IFRX) reported second-quarter 2026 results that missed analyst expectations on both the top and bottom lines, and the stock is being punished in pre-market trading. The company posted a non-GAAP loss per share of $0.095 against consensus estimates for a loss of $0.060, while revenue came in at zero versus a $3.57 million expectation, a gap largely tied to the wind-down of U.S. commercialization efforts.
Revenue and EPS versus estimates
The quarterly numbers represent a meaningful shortfall relative to the sell-side model. In the three months ended June 30, 2026, the company generated no product revenue, and costs remained elevated as clinical work on izicopan and vilobelimab continued.
The revenue miss was expected to some degree because the company exited commercial sales activities for vilobelimab at the end of 2025. Still, the size of the EPS gap and the absence of recognized revenue in a quarter where analysts had modeled for some contribution left the report comfortably below expectations.
What the press release highlighted
Clinically, management used the update to emphasize momentum around izicopan, the oral C5a receptor inhibitor that is now being positioned as the core growth driver. Phase 2 planning in ANCA-associated vasculitis (AAV) is underway, and the company is also evaluating izicopan in several renal indications, including atypical hemolytic uremic syndrome, IgA nephropathy and C3 glomerulopathy. Initial proof-of-concept data from those open-label studies are targeted for 2027.
The press release also drew attention to new preclinical data indicating that izicopan produces lower reactive metabolite formation than the marketed C5aR inhibitor avacopan, a potential safety differentiator. Following the EMA's CHMP recommendation to revoke marketing authorization for Tavneos in the EU, InflaRx has signaled it will engage with regulators on the most efficient development path for AAV in Europe, using both izicopan and vilobelimab.
Market reaction and outlook
The pre-market decline suggests investors were focused on the magnitude of the financial miss rather than the pipeline narrative. The company did not provide formal financial guidance in the release, so there is no updated company outlook to compare against the sell-side estimates for the upcoming quarters. That absence, combined with the wide earnings gap, likely leaves the initial trading reaction driven by the reported results themselves.
For investors who want to dig into the historical earnings behavior of the stock, a full earnings history is available. Those looking for the latest consensus expectations and forward projections can also review the current estimates page.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »